DDIT3 and diffuse large B-cell lymphoma: In this regard, a more mature 5-year follow-up of the REMoDL-B study showed that, whereas there was no overall benefit of adding bortezomib on PFS or OS in the overall population of the study, patients with ABC DLBCL experienced improved PFS and OS with bortezomib plus B-CHOP (5-year OS 67% with R-CHOP vs. 80% with RB-CHOP (HR, 0.58; 95% CI, 0.35 to 0.95; p = 0.032)).